N-Acetylgalactosaminyltransferase Engineering Service
Functions of Polypeptide N-acetylgalactosaminyltransferase (GALNT)
Glycosylation modification is an important post-translational modification of proteins. According to the different ways of linking the sugar chain and protein, glycosylation modification is mainly divided into two types: N-glycosylation and O-glycosylation. One of the most common O-glycosylation modifications is mucin-type O-glycosylation. With continuous research, more and more tumor markers are being discovered. These include several members of the GALNT family, which is the initiating enzyme that catalyzes mucin-type O-glycosylation. It affects the O-glycosylation of mucins, thereby influencing tumor cell genesis, prognosis, proliferation, and migration. To date, 20 isoforms of GALNT have been identified in humans. There are lots of research reports on GALNT related to cancer and other diseases.
The ability to precisely engineer GALNT to control glycosylation patterns is a major frontier in biotechnology, offering unprecedented opportunities to optimize therapeutic proteins and unlock new biological insights. At CD BioGlyco, our specialized GALNT engineering service is designed to harness this potential, providing a sophisticated platform for modifying proteins with high precision and efficacy.
Key Technologies
To overcome the inherent challenges of engineering glycosyltransferases, we employ precise gene editing technologies to design biological solutions with uniquely optimized properties tailored to your specific application. Our services range from improving enzyme kinetics to increase productivity to altering substrate specificity to develop unnatural glycans.
Driving Innovation Through Precision Glycoengineering with GALNT
CD BioGlyco is committed to being a reliable GALNT gene modification service partner. We have rich experience in cell lines and animal model construction.
Fig.1 One-stop GALNT gene modification process. (CD BioGlyco)
- Various GALNT gene modification service
Animal and cell line models are powerful tools for biomedical research. We have various types of mice and cell line models such as cancer cells, bone cells, etc. According to customers' needs, we develop Gene Editing Programs and construct gene modification models. Through overexpression, knockout, knockdown, and other different gene modification methods, we study the specific substrate of GALNT, its physiological function, and its application in the treatment of diseases.
GALNT2
GALNT2 modifies the O-glycosylation of ITGA5. It affects the activation of PI3K/Akt and MAPK/ERK pathways. Studies have shown that the knockdown of GALNT2 inhibits cell proliferation, migration, and invasion of non-small cell lung carcinoma cells. While the overexpression of GALNT2 resulted in the opposite.
GALNT3
GALNT3 affects the differentiation and prognosis of colon cancer cells. It may be a reliable diagnostic indicator for colon cancer. GALNT3 also affects the LDN-glycosylation of sclerostin, which may open up a new tool for the treatment of bone-specific osteoporosis.
GALNT6
GALNT6 is used as a molecular diagnostic marker for mammary carcinoma cell proliferation. Knockdown of GALNT6 inhibits cell migration and invasion of hepatocellular carcinoma (HCC) cells.
GALNT13
GALNT13 is highly correlated with the development and prognosis of myeloid neuroblastoma. It is used as a molecular marker for the diagnosis of myeloid neuroblastoma.
GALNT14
Mucin-type O-glycosylation in cancer varies in structure and amount, culminating in a unique glycan structure. GALNT14 plays an important role in a wide range of biological activities, including tumorigenesis, progression, invasion, migration, and apoptosis.
Workflow
Published Data
Paper Title: B4GALNT3 regulates glycosylation of sclerostin and bone mass
Technology: Gene Knockout, Gene Overexpression, Gene Silencing
Journal: EBioMedicine
IF: 11.1
Published: 2023
Results: B4GALNT3 expresses β-1,4-N-acetylgalactosaminyltransferase 3. Serum total sclerostin levels were elevated but serum LDN-glycosylated sclerostin levels were decreased in B4GALNT3 knockout mice compared to controls. The silencing of B4GALNT3 decreased the levels of LDN-glycosylated sclerostin, whereas overexpression of B4GALNT3 decreased the levels. B4GALNT3-mediated LDN-glycosylation of sclerostin may be a target for bone-specific osteoporosis.
Fig. 2 Changes in sclerostin levels in B4galnt3 knockout mice. (Movérare-Skrtic, et al., 2023)
Applications
- GALNT has diverse functions in different biological behaviors of tumor cells. Technologies for GALNT gene editing are used to develop new means of suppressing cancer cells.
- Technologies for GALNT gene editing are important for the study of the regulatory mechanisms of glycosylation and the functional roles of glycoproteins in life activities.
- Technologies for GALNT gene editing are used for the role of GALNT in inflammation and other diseases, which is expected to provide possible ideas for the search for novel markers and drug targets.
Advantages
- We optimize the experimental conditions. We improve the positive rate while reducing cytotoxicity, and have high editing efficiency and low off-target rate.
- We have a professional gene editing team to provide clients with experimental design, troubleshooting, data analysis, and other services.
- We provide a one-stop service for GALNT gene editing. Sequence design, vector construction, mutant construction, and other experiments can be completed.
Frequently Asked Questions
CD BioGlyco has undergone continuous research to minimize the time required to prepare gene-edited cells and animal models. We use optimized technologies for gene editing to precisely modify genes. If you are interested in our GALNT gene modification service, please feel free to contact us.
Associated Services
To further bolster your research and development endeavors, CD BioGlyco provides a suite of supplementary services that integrate seamlessly with your GALNT engineering project. Our objective is to deliver a holistic, start-to-finish solution addressing all your glycobiology requirements.
Glycosylation Analysis: We deliver extensive services for in-depth examination of glycan structures. This encompasses determining the exact sequence of monosaccharides within your glycan chain, identifying the specific glycosidic bond types linking sugar units, and employing high-resolution mass spectrometry (MS) to detect and quantify glycan structures.
Glyco-engineered Expression: Our cutting-edge facilities offer tailored protein expression services for producing your target protein. We provide multiple expression systems, such as mammalian cell expression, Pichia pastoris expression, and plant-based expression systems.
Reference
- Movérare-Skrtic, S.; et al. B4GALNT3 regulates glycosylation of sclerostin and bone mass. EBioMedicine. 2023, 91: 104546. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




